Horizon Pharma (HZNP) Tops Q1 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Horizon Pharma Plc (HZNP) Should Benefit From M&A - Mizuho
May 10, 2016 6:37 AM EDTMizuho analyst, Irina Koffler, trimmed her PT on Horizon Pharma (NASDAQ: HZNP) to $24 from $25 while maintaining her Buy rating. Despite seeing a challenging 2016, she thinks the company should benefit from M&A making the risk/reward is still attractive.
HZNP reported 1Q:16... More
